Curedisc

Curedisc is a South Korean biotechnology company focused on the development of advanced mRNA-based therapeutics and vaccines. The company utilizes its proprietary Cure-LNP (Lipid Nanoparticle) platform, which is designed to optimize the delivery and stability of mRNA molecules for improved therapeutic outcomes. Curedisc's research and development efforts are primarily directed toward infectious disease prevention and oncology treatments. Their pipeline includes a next-generation mRNA vaccine for COVID-19 and therapeutic candidates for solid tumors such as melanoma. By combining innovative mRNA engineering with specialized delivery technology, Curedisc aims to establish a leading position in the global RNA medicine market. The company was founded by Professor Yoo-Kyoung Oh, a recognized expert in drug delivery systems from Seoul National University.